Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging

Despite adoption of molecular biomarkers in the management of non-small cell lung cancer (NSCLC), the recently adopted 8th Edition staging utilized only clinicopathologic characteristics, and validated improvement in risk stratification of early-stage disease remains elusive. We therefore evaluated the integration of a clinically-validated molecular prognostic classifier into conventional staging....

Incorporation of a molecular prognostic classifier significantly improved identification of high-risk patients and survival predictions compared to conventional staging. TNMB may lead to improved survival of early-stage disease through more effective application of adjuvant therapy.